Loading clinical trials...
Loading clinical trials...
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Conditions
Interventions
Dazostinag
Pembrolizumab
+2 more
Locations
62
United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCI Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
University of California Los Angeles - Jonsson Comprehensive Cancer Center
Santa Monica, California, United States
SCRI - HealthOne Denver
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Start Date
July 22, 2020
Primary Completion Date
March 30, 2026
Completion Date
March 30, 2026
Last Updated
April 8, 2026
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions